Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like Strongbridge Biopharma Banks $53 Million Financing From July 16, 2017 Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series To End The Opioid Crisis: Development Of Safe, Effective, Non-Addictive Pain Treatments June 11, 2017 FDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug April 18, 2017
Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series To End The Opioid Crisis: Development Of Safe, Effective, Non-Addictive Pain Treatments June 11, 2017